Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

payer survey

Genesis Research – an introduction

Genesis Research Group

- PMLiVE

Novo Nordisk announces positive phase 3 results for haemophilia treatment

Haemophilia affects around 1,125,000 people globally

- PMLiVE

Sanofi and Sobi announce positive phase 3 trial results for severe haemophilia A

Results from the study showed once-weekly efanesoctocog alfa doses provided ‘clinically meaningful’ bleed protection for patients with severe haemophilia A

Ensuring fit-for-purpose real-world data to generate real-world evidence with Susan Oliveria

Genesis Research Group

Genesis Research at the World EPA Congress 2022

Genesis Research Group

- PMLiVE

GSK creates new consumer healthcare business, Haleon

Haleon, whose brand portfolio will include Sensodyne toothpaste and Panadol painkillers, is the combination of the consumer health businesses of GSK and Pfizer

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

- PMLiVE

Celebrating the 2022 Communiqué Awards

The Awards, held at the London Grosvenor House Hotel, recognise excellence in medical affairs and healthcare communications

Traversing the Medtech Regulatory Landscape in the Interest of Patients

Dr. Bassil Akra, CEO of AKRA TEAM GmbH, takes a deep dive into the new approval process for medical devices in the EU and shares how his company is supporting...

Impetus Digital

- PMLiVE

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

If approved, this could be the first such antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma

- PMLiVE

Pfizer’s Paxlovid given FDA permission to be prescribed by US pharmacists

Under the Emergency Use Authorisation revision, pharmacists will be able to prescribe the COVID-19 treatment to patients, providing they meet certain conditions

- PMLiVE

BeiGene and InnoRNA join to research novel mRNA therapies

BeiGene will hold exclusive global development and commercialisation rights for the jointly discovered mRNA-LNP therapies

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links